Oligonucleotide-based therapeutics are set to transform the landscape of treatable human disease. Many traditional pharmacological treatments use small molecules to directly modulate the activity of proteins involved with disease. Yet only about 25% of disease-related proteins have been drugged to date, and the vast space of the human genome provides a variety of biochemical mechanisms to target for treating disease.
Nucleic acid therapies act before protein production, provide instructions for functional proteins, or initiate degradation. While creating oligonucleotide therapeutics is theoretically as straightforward as a sequence of chemical building blocks, designing effective treatments for clinical applications involves understanding both the chemistry and biology of nucleic acids.
Copyright © 2024 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy